1 / 30

Introductions and complications of Diabetes Mellitus

Introductions and complications of Diabetes Mellitus. Dr. Nakwagala Fred Senior Consultant Physician Mulago National referral hospital 17 Oct 2018. What is diabetes?.

vass
Download Presentation

Introductions and complications of Diabetes Mellitus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Introductions and complications of Diabetes Mellitus Dr. Nakwagala Fred Senior Consultant Physician Mulago National referral hospital 17 Oct 2018

  2. What is diabetes? • Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. • The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. • The effects of diabetes mellitus include long–term damage, dysfunction and failure of various organs.

  3. What is diabetes? • Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. • The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. • The effects of diabetes mellitus include long–term damage, dysfunction and failure of various organs.

  4. DM and Survival

  5. Types of Diabetes • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • Gestational Diabetes • Other types: • LADA (Latent Autoimmune Diabetes of Adults} • MODY (maturity-onset diabetes of youth) • Secondary Diabetes Mellitus

  6. Q1. How is diabetes screened and diagnosed? Criteria for Screening for T2D and Prediabetes in Asymptomatic Adults *At-risk BMI may be lower in some ethnic groups; consider using waist circumference. †Obstructive sleep apnea, chronic sleep deprivation, and night shift occupations. BMI = body mass index; BP = blood pressure; CVD=cardiovascular disease; HDL-C = high density lipoprotein cholesterol; IFG = impaired fasting glucose; IGT = impaired glucose tolerance; NAFLD = nonalcoholic fatty liver disease; PCOS = polycystic ovary syndrome; T2D, type 2 diabetes.

  7. Q1. How is diabetes screened and diagnosed? Diagnostic Criteria for Prediabetes and Diabetes in Nonpregnant Adults FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; PG, plasma glucose.

  8. Acute and chronic complications Acute Chronic Microvascular Opthalmopathy Nephropathy Neuropathy Macrovascular diseases Cardiovascular Peripheral vascular disease Cerebral Vascular Disease • - diabetic ketoacidosis (DKA) • - hyperglycemic Hyperosmolar Syndrome (HHS) • - hypoglycemia • - Metformin associated lactic acidosis, MALT

  9. Effect of Hyperglycemia • Acute, reversible intracellular metabolic changes • Cumulative, irreversible effects on stable macromolecules

  10. Good glycemic control decreasesthe diabetic complications • In the DCCT trial by reducing HBA1c from 9 % to 7% the following reductions occurred. • Retinopathy 76% • Nephropathy 54 % • Neuropathy 60 % • Macro vascular 41 %

  11. Acute, reversible intracellularmetabolic changes • Increased activity of polyol pathway • Modified protein kinase C activity • Early glycation products • Increased production of free radicals

  12. Consequences of increasedprotein kinase C (PKC) activity

  13. Biochemistry pathways

  14. Effects of advanced glycationend products (AGE) • Crosslinking of extracellular proteins • Interactions with specific AGE receptors • Crosslinking with intracellular DNA

  15. Hemodynamic disturbancesin diabetes • Increased blood flow • Increased permeability • Hemorrheological and coagulation abnormalities - increased plasma viscosity - decreased red-cell deformability - increased platelet aggregability

  16. Structural abnormalitiesin diabetes • Leakage of glycated plasma proteins • Extracellular matrix is increased - BM is thickened - mesangial matrix is expanded - collagen is increased • Hypertrophy and hyperplasia of endothelial, mesangial and arterial smooth muscle cells

  17. Diabetes and infections • Infections are more frequent: pneumonia, urinary tract, skin and mucosal infections 1.5-2 x ↑ • Infections are more severe, mortality rate is increased 2-3x ↑. • Provokes hyperglycemic crisis. • Rare, life threatening infections. • Immunization: annually influenza vaccine, pneumococcal polysaccharid vaccine > 2 years (repeat > 64 years of age, renal disease, transplantation)

  18. Rare, life threatening infections.in diabetes • Rhinocerebral Mucormycosis • Malign otitis externa (Ps. aeruginosa) • Psoas abscessus (St. aureus) • Emphysematosus cholecystitis (E. coli, Cl. Perfringens) • Emphysematosus urocystitis, pyelonephritis (E. coli, K. pneumoniae) • Necrotising Fasciitis (polymicrobe)

  19. DM Autonomic Neuropathy

  20. Classification of diabetic neuropathy • Diffuse neuropathy -somatic np.: sensorimotor - autonomic np.: cardiovascular, gastrointestinal, genitourinary, pupil • Focal syndromes - focal np.: mononeuritis, entrapmentsyndr. - multifocal np.: proximal neuropathies • Subclinical neuropathy - abnormal electrodiagnostic tests - abnormal quantitative sensory tests - abnormal autonomic function tests

  21. Cardiovascular risk in diabetes • Peripheral arterial disease 2-4x ↑ (risk of amputation 16x ↑) • CHD: risk of AMI 2-3x ↑, heart failure 5x ↑ • Stroke 2-4 x ↑ • Protection of female gender is disappeared • The macrovascular risk is 10 x ↑ in the presence of microvascular complication

  22. Q12. How is CVD managed in patients with diabetes? Comprehensive Management of CV Risk • Manage CV risk factors • Weight loss • Smoking cessation • Optimal glucose, blood pressure, and lipid control • Use low-dose aspirin for secondary prevention of CV events in patients with existing CVD • May consider low-dose aspirin for primary prevention of CV events in patients with 10-year CV risk >10% • Measure coronary artery calcification or use coronary imaging to determine whether glucose, lipid, or blood pressure control efforts should be intensified CV = cardiovascular; CVD = cardiovascular disease.

  23. Q12. How is CVD managed in patients with diabetes? Statin Use • Majority of patients with T2D have a high cardiovascular risk • People with T1D are at elevated cardiovascular risk • LDL-C target: <70 mg/dL—for the majority of patients with diabetes who are determined to have a high risk • Use a statin regardless of LDL-C level in patients with diabetes who meet the following criteria: • >40 years of age • ≥1 major ASCVD risk factor • Hypertension • Family history of CVD • Low HDL-C • Smoking ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; HDL-C = high density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.

  24. DM Nephropathy

  25. Q9. How is nephropathy managed in patients with diabetes? Assessment of Diabetic Nephropathy • Annual assessments • Serum creatinine to determine eGFR • Urine AER • Begin annual screening • 5 years after diagnosis of T1D if diagnosed before age 30 years • At diagnosis of T2D or T1D in patients diagnosed after age 30 years AER = albumin excretion rate; eGFR = estimated glomerular filtration rate; T1D = type 1 diabetes; T2D = type 2 diabetes.

  26. Diagnosis and treatment ofMicroalbuminuria • Screening once a year in T1DM (at least), at diagnosis in T2DM • Urinary albumin excretion 30-300 (299) mg / 24 h • 2 positive out of 3 samples (collected urine) (fever, urinary tract infection, heart failure etc.) • ACE-inhibitors (ARB), good metabolic control • DM + albuminuria increases the CVD mortality with 20 x

  27. Q9. How is nephropathy managed in patients with diabetes? Staging of Chronic Kidney Disease CKD = chronic kidney disease; GFR = glomerular filtration rate; NKF = National Kidney Foundation. Levey AS, et al. Kidney Int. 2011;80:17-28.

  28. Q10. How is retinopathy managed in patients with diabetes? Assessment of Diabetic Retinopathy • Annual dilated eye examination by experienced ophthalmologist or optometrist • Begin assessment • 5 years after diagnosis of T1D • At diagnosis of T2D • More frequent examinations for: • Pregnant women with DM during pregnancy and 1 year postpartum • Patients with diagnosed retinopathy • Patients with macular edema receiving active therapy DM = diabetes mellitus; T1D = type 1 diabetes; T2D = type 2 diabetes.

  29. Q10. How is retinopathy managed in patients with diabetes? Management of Diabetic Retinopathy • Slow retinopathy progression by maintaining optimal control of • Blood glucose • Blood pressure • Lipids • For active retinopathy, refer to ophthalmologist as needed • For laser therapy • For vascular endothelial growth factor therapy DM = diabetes mellitus; T1D = type 1 diabetes; T2D = type 2 diabetes.

  30. Q10. How is retinopathy managed in patients with diabetes? Management of Diabetic Retinopathy • Slow retinopathy progression by maintaining optimal control of • Blood glucose • Blood pressure • Lipids • For active retinopathy, refer to ophthalmologist as needed • For laser therapy • For vascular endothelial growth factor therapy DM = diabetes mellitus; T1D = type 1 diabetes; T2D = type 2 diabetes.

More Related